FDA daily

FDA daily for Tuesday, April 21, 2026

In this issue: 2 shortage updates, 11 approvals and 22 device decisions.

Drug shortages

FDA date:

FDA updated 2 shortage entries on Mon, Apr 20: 2 new, 2 to be discontinued.

Browse drug shortages in FDA data →

Drug and biologic approvals

FDA date:

On Tue, Apr 14 FDA approved 1 new application (0 brand or biologic, 1 generic) and 10 supplements to existing ones.

  • CANAGLIFLOZIN

    APOTEX · CANAGLIFLOZIN

    ANDA210449Generic (ANDA)Discontinued
Browse drug and biologic approvals in FDA data →

Device clearances and approvals

FDA date:

FDA decided 14 510(k)s and 8 PMA decisions on Tue, Apr 7.

Browse device clearances and approvals in FDA data →

FDA did not answer for Drug recalls, Labels, Device recalls, Food and supplement recalls while this issue was written; those sections will fill in on a later visit.

How the FDA daily is written

Every issue is written from FDA's public data (openFDA) and nothing else: the counts, names, firms and reasons are FDA's own. openFDA posts each kind of record on its own delay, so each section covers one FDA date and says which. Shortages cover yesterday; approvals, drug and device recalls, and food and supplement recalls cover a week ago; device clearances and label changes cover two weeks ago. Every FDA date appears in exactly one issue. Complete response letters appear the day after FDA publishes a batch.

Subscribe with any feed reader, or point an email tool at the RSS feed to send each issue as a newsletter. Search any drug, device or company across every FDA dataset in the FDA data explorer.

Read FDA's day. Stock your practice.

Join free with your NPI: wholesale pricing from verified vendors, with the FDA and state rules for each category one click away.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.